Additional file 2: of Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity

Figure S1. Profiling of immune cells in mouse lung tumor microenvironment: Top: Gating strategy for alveolar macrophages, neutrophils, and other myeloid cells. Bottom left: Lung weights in mg. Bottom right:Quantification of Alveolar macrophages, neutrophils, lymphocytes, and other rare types. Figure S2. Expression of myeloid markers and ARG1 and ARG2 in all cell types in the lung tumor microenvironment in published dataset. Figure S3. Analysis of staining for myeloid marker CXCR2 and ARG1 in NSCLC TMA. Figure S4. Correlation of Cd66b, and Arginase, and CD3 in multiplex IHC stained Tissue microarray. Figure S5. Evaluation of the activity of Cpd 9 at different doses and Arg1 expression in peritoneal macrophages. Figure S6: CD11b + MDSCs sorted from ID8 tumor ascites reduced of IFNg secretion by splenocytes. Figure S7. Arginase inhibitor sensitivity correlates with Arginase expression in cancer cell lines. (PDF 1331 kb